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Abstract
Objective: Cost-effectiveness evaluations or budget impact analysis represent a typical example of decision analysis problems. In this study, we aim to provide 
an introduction to these so called decision-theoretic networks. A formal introductory background is followed by an example of a cost-effectiveness evaluation of 
cardiovascular therapy. 
Methods: Using a Markov CVD model, we compared 6 strategies for initiation of drug treatment-2 different blood pressure levels (165/95 and 145/90 mm Hg) 
and 4 different levels of absolute cardiovascular risk over 10 years (45%, 35%, 25%, and 15%). We modeled a hypothetical cohort of all adults without cardiovascular 
diseases in Italy over 10 years. 
Results: The incremental cost-effectiveness ratios for treating those with 10-year absolute risk for cardiovascular diseases >45%, 35%, 25%, and 15% were Euro 
450, 1000, 2800, and 6 000 ,respectively per quality-adjusted life-year (QALYs)gained, respectively. Strategies based on a target blood pressure level were both 
more expensive and less effective than treatment decisions based on the strategy that used absolute cardiovascular risk of >15%. Sensitivity analysis of cost of 
treatments, prevalence estimates of risk factors, and benefits expected from treatment did not change the ranking of the strategies. National inpatient hospital costs 
for hypertensive patient with complications were nearly Euro 2.8 billion in 2012. 
Conclusions: This may suggest that quality of life is a more subjective and less tangible outcome for decision-makers than patients cured, strokes averted, or years of 
life saved. QALYs are the preferred outcome measures in a number of formal guidelines for conducting pharmacoeconomic analyses.
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Introduction
The rapidly rising cost of drug therapy is a concern to healthcare 
providers throughout the world, particularly as new drugs frequently 
offer only marginal improvements over existing therapies but at 
substantially increased costs [1]. As a result, decision-makers at all 
levels (national, regional, hospital, primary care, or managed care) are 
faced with difficult choices about which drugs to make available to their 
patients or members. One means of controlling costs is the development 
of a formulary, resulting from explicit decision-making to include or 
exclude particular medications from the range of drugs available to be 
prescribed. Several decision-making criteria and methods for selecting 
drugs for formulary inclusion have been suggested, but the role of 
pharmacoeconomic information in this process remains somewhat 
unclear. The World Health Organization (WHO) describes broad 
criteria to be considered in making formulary decisions but does not 
attach relative importance to the individual criteria [2]. Decisions about 
drug selection are complex and are influenced not just by evidence-
based criteria but also take into account the political, social, and ethical 
values of the community to which the decisions apply. A number of 
frameworks have been proposed to limit the influence of “emotional 
criteria” on decision-making and to assign relative weight to each 
criterion in terms of importance [3]. Another formal scoring system 
based on quality and cost factors has been used to assign priorities for 
purchasing drugs within a limited hospital drug budget [4]. “Quality” 
components in this model include individual patient benefit, mortality/
morbidity of the condition to be treated, evidence from literature, type 
of treatment (well-established or trial), and clinical comparison with 
other treatments. “Cost” components include comparison with other 
treatments, total cost per year, and cost per patient. The similarities 
in the key criteria examined (efficacy, safety, drug characteristics, 
pharmacokinetics, formulation, dosage regimen) suggest the possibility 
of a decision-making framework that could be broadly applicable across 
settings, both in developed and developing countries. An area less 
clearly articulated, however, is where and how cost information should 
be incorporated in decision-making. An increasing number of national 
or regional organizations now require pharmacoeconomic information 
about a drug to be included in submissions for reimbursement or 
listing [5]. Despite advances in treatment, cardiovascular disease is 
expected to be the leading cause of death and disability worldwide by 
2020 [6]. Among risk factors for cardiovascular disease, hypertension 
is responsible for more deaths worldwide than any other, including 
cholesterol, tobacco, body mass index, and physical activity [7]. Hence, 
the social and economic demands of adequately treating hypertension 
are of considerable magnitude and complexity. The blood pressure 
level-approach based on a single cutoff point does not differentiate risk 
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A Markov model was used to assess the cost-effectiveness of the 
six alternative guidelines for hypertension in an hypothetical cohort of 
healthy individuals [13]. The population was stratified by gender, age, 
systolic blood pressure, smoking, diabetes mellitus and cholesterol. 
The time horizon of the model was ten years and the cycle length was 
one year. The population started the simulation free of cardiovascular 
disease (Figure 1). Every year individuals could remain disease free, 
die of non- cardiovascular disease causes, or develop fatal or nonfatal 
cardiovascular disease. At the end of each year, the population 
was redistributed to one of several health states, depending on the 
events of the previous year. Such health states were disease free (no 
cardiovascular disease event or death of other causes), post-arrest, 
post-MI without coronary artery bypass grafting (CABG), post-MI 
with CABG, post-angina without CABG, post-angina with CABG, 
post-cerebrovascular accident, and death (both non- cardiovascular 
disease -related and cardiovascular disease -related death). Table 1 
shows assessed outcomes.
In the economic analysis both future costs and benefits were 
discounted at 3% per year, consistent with current guidelines. Effects 
were measured in years of life and quality-adjusted life-years (QALYs) 
gained. Quality-adjusted life-years were the most appropriate benefit 
measure because they capture the impact of the intervention on the two 
most important dimensions of health for patients with hypertension 
(i.e. quality of life and survival). Quality-adjusted life-years are 
comparable with the benefits of other health care interventions [14].
Sensitivity analysis
Univariate sensitivity analyses were carried out to assess the 
robustness of cost-utility estimates to variations in the model inputs, 
such as -costs of hypertension treatment:- cost per hospital diagnosis;-
proportion of patients undergoing CABG or angiography;-proportion 
of the population receiving anti-hypertensive treatment;-prevalence 
of hypercholesterolemia ;-relative risk reduction from treatment and 
discount rate. A probabilistic multivariate sensitivity analysis was also 
performed, using Monte Carlo simulation, in which the previously 
mentioned inputs were varied simultaneously. Traditionally, with a 
decision tree (or Markov state-transition model) the most common 
way of performing probabilistic sensitivity analysis is by means of 
simulation procedures, such as Monte Carlo or Markov Chain Monte 
Carlo simulation. With these procedures, the model is iteratively 
analyzed. At each step, the input parameters are sampled from a 
suitable probability distribution, reflecting the likelihood of each input 
value. As a result, a distribution of the outcomes or expected utility 
is obtained, reflecting the underlying uncertainty, and allowing its 
quantification [15] (Figure 2). 
Results
The proportion of eligible patients receiving anti-hypertensive 
treatment was 44% (range: 32 to 56). The reduction in systolic blood 
pressure with drug treatment was 10 mmHg. The cardiovascular 
disease risk reduction with drug treatment was 14% (range: 14 to 
25), while the stroke risk reduction was 40% (range: 10 to 50). Table 
2 shows, over a 10-year timeframe, the expected quality-adjusted life-
years (in millions) in a population of 7240 individuals. In Figure 3 
QALYs is presented by discrete second order probability distributions. 
When the nodes Probability Early Switch and Uncertainty Monetary 
value QALYs are instantiated at a certain value. Since the likelihood 
of the instantiated values of Probability Early Switch and Uncertainty 
based on age, actual level of cholesterol, smoking, or the number of 
other risk factors present. Consequently, this method does not allow 
for precise assessment of a patient’s true cardiovascular risk. The WHO 
CHOICE (World Health Organization Choosing Interventions that are 
Cost-Effective program) program showed that the strategy of treating 
those at high absolute risk in various regions of the world was cheaper 
and saved more lives than one based on target levels of individual risk 
factors. However, the model is limited by its use of regional rather 
than national epidemiology and cost estimates. These limitations are 
particularly important because the distribution of hypertension differs 
by geography and ethnicity, as much as does the extent of economic 
development in different countries [8,9]. Cost-effectiveness evaluations 
represent a typical example of such a problem, as they are performed 
for decision making regarding reimbursement of drugs or health care 
budget allocation, in presence and under the influence of random 
variables. Standard tools for pharmacoeconomic evaluations include 
regression techniques and decision-analytic models, e.g. decision 
trees, Markov state-transition models, and discrete event simulations. 
Decision trees are so far the most used tool to support decision making 
under uncertainty. The decision problem is represented by means of 
a tree-like structure combined with conditional probabilities and utilities 
(e.g. costs, quality of life multipliers) associated with the different decisions. 
Decision trees have a direct connection to expected utility theory, and are 
generally good for (deterministic) sensitivity analysis [10,11]. 
Methods
We conducted a cost-effectiveness analysis of blood pressure 
level- and absolute risk-based hypertension guidelines in persons 
without known cardiovascular disease or target-organ disease [12]. The 
strategies compared included: two different strategies based on blood 
pressure levels (initiation of treatment for those with blood pressure 
higher than 165/95 or 145/90 mm Hg and diabetes mellitus), four 
different strategies based on the absolute level of cardiovascular risk 
over ten years (45%, 35%, 25% and 15%) according to the standard of 
care currently in practice. There have been no trials that compared the 
different hypertension guidelines. Even if these trial data did exist, they 
likely would not be for the length of time we chose to evaluate, and we 
therefore chose to model cardiovascular disease.
Seven thousands two hundred forty people, were selected from 
the database of outpatient clinic in primary health care in Federico 
II University Hospital of Naples, Italy. Patients were recruited for the 
study during their annual checkup at the outpatient clinic. All patients 
had a previously established diagnosis of essential hypertension (at 
least for 1 year). The possible causes of secondary hypertension were 
excluded (no clinical signs, normal results of serum urea, creatinine, 
and electrolytes, normal urinary excretion of catecholamines, and 
normal renal imaging studies, including radionuclide renogram and/or 
intravenous urography and/or ultrasound scan). All participants were 
white, were stratified into 20 groups representing each of the possible 
combinations of the 6 characteristics: sex, age, systolic blood pressure, 
smoking, diabetes mellitus, and cholesterol. Age was stratified into 5 
deciles (34 to 44, 45 to 55, 56 to 66, 67 to 77 and 78 to 88 years). There 
was further stratification by systolic blood pressure into 3 groups: <140 
mm Hg, 140 to 160 mm Hg, and >160 mm Hg. Single BP measurements 
were taken at baseline, and comorbidity and medication data were 
collected only at baseline.  Further dichotomization was done for 
smoking and diabetes mellitus. Finally, the stratifications were divided 
according to 3 levels of total cholesterol: <190 mg/dL, 190 to 270 mg/
dL, and >270 mg/dL. The distributions of cholesterol and diabetes 
mellitus were stratified with mean values according to sex, because few 
data exist to determine their relationship to the other risk factors.
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CHD: coronary heart disease; CVA: cerebrovascular accident; Med Rx treatment; MI:  myocardial infarction.
Figure 1. Schematic of CVD model. The full model represented by this simplified version has 62 possible clinical pathways. All members of the cohort begin free of CVD disease. In the 
initial year, each member of the cohort has a certain probability based on treatment status risk factors of moving along 1 of 4 pathways: remaining disease free, dying of non-CVD causes, 
or developing fatal or nonfatal coronary heart disease or stroke. In the subsequent years, those with prior CVD follow a separate pathway with adjusted risks for recurrence of CVD or death 
based on age and prior event. All risks are updated annually based on age. Costs are captured along the way for treatment of hypertension and CVD events. 
Which 
antihypertensive 
therapy? 
Cost up to 
switch
Probabily 
early switch
Figure 2. Influence diagram of antihypertensive treatment.
Tx: antihypertensive treatment
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Monetary value QALYs is defined by their marginal distributions the 
likelihood of expected utility is obtained free of charge. For example, 
Pr(Probability Early switch = 0.05) equals 6.63% and Pr(Uncertainty 
Monetary value QALYs = e250,000) equals 6.25% for antihypertensive 
therapy. The corresponding expected utility is e151,752 with a 
likelihood of 0.40%. Over a 10-year timeframe, the expected costs (in 
millions) in a population of 7240 individuals were showed in table 3.
Synthesis of costs and benefits 
Incremental cost-effectiveness ratios and cost-utility ratios were 
calculated to combine the costs and benefits of each strategy with the 
next less effective option. The two strategies based on target BP levels 
were dominated as they were both less effective and more expensive 
than absolute risk options. Again, the two strategies based on target 
blood pressure levels were dominated. The sensitivity analysis showed 
that changes in model inputs did not alter the ranking of the strategies. 
Only when the annual cost of hypertension treatment fell below the 
threshold point of € 30 did the strategy with absolute CVD risk of > 
40% become less expensive and more effective than the no-intervention 
strategy. In this high-risk population, the number needed to treat to 
prevent 1 event was low enough that below €30 per year of treatment, 
the reduction in costs from preventing events was greater than the 
cost of treating those who would not have an event over the 10 years. 
Above €30 per year of antihypertensive therapy, the ranking of the 
strategies was the same as in the base case, with no treatment having 
the lowest costs and benefits and the 4 absolute risk strategies each 
with successive incremental cost-effectiveness ratiosThe multivariate 
sensitivity analysis showed that the base-case results were quite robust 
to variations in model assumptions. National inpatient hospital costs 
for hypertensive patient with complications were nearly Euro 2.8 
billion in 2012. The risk of hospitalization from cardiovascular disease 
is two to four times higher for women with diabetes and hypertension 
compared to women without diabetes. 
Discussion
In this paper, we presented an introduction to decision-theoretic 
networks, with specific applications to cost- effectiveness evaluations. 
While this tool has been widely used in other research fields, it has been 
so far neglected by the pharmacoeconomics community. The clinical 
experts play a crucial role in the definition of the network structure, and 
joining statisticians or economists in drawing a graph is surely easier 
(and funnier) than writing mathematical equations. We reckon that 
statistical, economic and clinical research is to be focused on that topic 
in the next future. A decision network (an equivalently, an influence 
diagram) is a belief network that is augmented to represent the 
alternative actions available to a decision maker (with decision nodes) 
and his preference for alternative states (with a value node). In terms of 
the construction of network, we would like to be able to construct the 
value node from sentences in the our database as well as incorporate 
decision nodes in the construction process. A value function is a 
mapping from the various possible outcomes or states resulting in 
particular decision problem to a single real number. In a decision 
network, there is a single value node. A value function for medical 
treatment might look something like the following, where Patients 
value (v,p) stands for the relation ‘’ Patient p’s value is v’’. The value v is 
the value variable in this predicate. Direct specification of such a table 
of possible decision a situation is unwieldly and furthermore is subject 
to exactly the type of inflexibility a lack of context sensitivity that we 
encounter with fixed probabilistic model. We therefore construct these 
structures based on the set of deterministic dependencies, facts and 
alternative outcomes in the database. 
Another interesting feature of decision-theoretic networks is 
that, since they represent a model for the entire joint probability 
distribution of a set of variables, there is no need for the definition of 
“dependent” (response) and “independent” (covariates) variables. Each 
node is evaluated in terms of the dependence relations with the others, 
overcoming the limitation of some regression models, where a given 
form of causality is given as an assumption, without the possibility of 
learning over it [16]. Therefore, decision-theoretic networks distinguish 
themselves from standard regression models as they try to manifest 
not only the correlation between the covariates and the response 
variable, but also the correlation between the different covariates. This 
is useful both when the researcher tries to capture the effects of indirect 
influences, and when some important covariate is missing from the 
dataset. While we strongly advocate the use of graphical models, we 
Outcomes assessed
-hypertension and smoking prevalence
-10-year CVD risk
-10-year coronary heart disease (CHD) risk
-10-year stroke risk
-non-CVD mortality
-the proportion of eligible people receiving anti-hypertensive treatment 
-treatment effects in terms of BP reduction 
-CHD reduction and stroke reduction
Table 1. The utility adjustments used to calculate quality-adjusted life-years (QALYs) were 
also derived from the literature.
Cost, 
€Millions 
Incremental 
Cost,† 
€Millions 
Effect, 
QALYs 
(Millions)
Incremental 
Effect,† 
QALYs 
Incremental 
C/E Ratio† 
€/QALY
No treatment 3460 … 44.694 … …
Absolute risk 
CVD >40%
3464 4 44.700 6.000 700 
Absolute risk 
CVD >30%
3491 27 44.721 21.000 1300 
Absolute risk 
CVD >20%
3671 180 44763 42.000 4300 
Absolute risk 
CVD >15%
3746 85 44.781 18.000 6.000 
2000 Italian 
guidelines 
(target level 
160/95 mm Hg)
3900 154 44.760 −21 000 Dominated‡ 
Current 
guidelines 
(target level 
145/90 mm Hg)
4200 300§ 44.279 −2000 Dominated 
†Each strategy’s cost and effect are compared with the preceding less costly one.
‡A dominated strategy is one that is both more expensive and less effective than the 
preceding strategy to which it is compared.
§Compared with absolute risk CVD >15%, because the 2000 guidelines are dominated by 
the absolute risk CVD >15% strategy.
Table 2. Estimated benefits used in the economic analysis. Over a 10-year timeframe, the 
expected QALYs (in millions) in a cohort of 7240 individuals.
€ 460 with no intervention,
€ 450 with the strategy of drug intervention for absolute CVD risk of > 45%,
€1000 with absolute CVD risk of > 35%,
€ 2800 with absolute CVD risk of > 25%,
€ 6000 with absolute CVD risk of > 15%,
€ 6100 with the strategy of drug intervention for BP level higher than 165/95 mmHg, and
€ 6,735 with a target BP level of 145/90 mmHg
Table 3. Cost results. Over a 10-year timeframe, the expected costs (in millions) in a 
population of 7240 individuals were.
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Figure 3. Prior probability distribution for probability early switch and uncertainty mon value QALYs. Graphs are presented for antihypertensive therapy.
acknowledge some limitations of decision-theoretic networks. Unlike 
decision trees assumes symmetry (i.e. every scenario consists of the 
same sequence of variables). Moreover, complex problems may require 
a large number of probability assessments [17]. On the one hand, it is 
often the case that variables of interests (such as rates of occurrence 
of a given disease, or costs associated with this disease) are naturally 
defined over a continuous scale. However, it is possible to approximate 
this reality, making these variables discrete (possibly using a large grid 
of plausible values). On the basis of the results of our population-based 
simulation model, we conclude that for the current Italian population, 
hypertension guidelines based on an absolute risk for cardiovascular 
disease are both more effective at saving lives and less costly than those 
based predominantly on a blood pressure level. This approach is even 
more attractive if the cost of treatment could be reduced. We modeled the 
cost of hypertension treatment based on the current mix of medications 
used in Italy. If the use of thiazides replaces the more expensive calcium 
channel blockers or ACE inhibitors, then the cost-effectiveness ratios 
for primary prevention will be further reduced, and the absolute risk 
strategies will be even more attractive, if not economically dominant, 
compared with no treatment. Furthermore, the conventional blood 
pressure–based guidelines remained more costly and less effective with 
each univariate and multivariate sensitivity analysis. We recognize that 
our model is based on limited cost data, which is a significant problem 
throughout the developing world. However, given that we applied the 
same costs of treatment to all the intervention strategies, the results 
seen in the sensitivity analysis still showed that the blood pressure level 
guidelines were always dominated throughout the assessed ranges 
of costs. Certainly, the costs of interventions could be much lower if 
generic medications were used instead of the current pattern of use 
of both patented and generic drugs in Italy. Thus, our estimates are 
likely conservative. However, under this criterion, the absolute risk of 
15% strategy would also be acceptable if a greater proportion of generic 
medications, such as hydrochlorothiazide, were used. Antihypertensive 
medication may be expected to have two opposing effects on quality of 
life: improvements through the reduced incidence of cardiovascular 
events and reductions through the impact of treatment-related 
adverse effects. The latter could potentially be important in assessing 
the balance between benefits and harms, particularly for low-risk 
individuals. Differences in adverse effects between the drugs could also 
have an influence on their relative cost effectiveness. A Medline search 
was done to identify utility estimates that could be used to reflect the 
latter for the included drug classes. Some studies were identified that 
estimated the incidence of drug-related adverse events and quality of 
life [18,19]. However, none of these included data in a form suitable 
for estimation of utilities. Most published cost-effectiveness studies 
have assumed zero, or minimal (0.01), loss of quality of life due to 
treatment-related side effects according to Harvard CEA Registry264 
[20]. Where these have compared different antihypertensive 
medications, they have generally assumed equal utility loss from 
adverse effects of treatment [21]. Few studies have directly measured 
treatment utilities from patients. The economic analysis of the SCOPE 
trial included direct assessment of utility using the EuroQoL health 
status measurement instrument [22]. This estimated a mean change 
in utility of minus 0.03 for the candesartan group and minus 0.05 for 
the mixed hypertensive treatment control group over a mean follow-
up of 3.7 years. However, it is not possible to separate out the impact 
of treatment side effects, or to attribute utility losses to individual 
drugs. Another cost-effectiveness study estimated utilities from 148 
hypertensive patients using the standard gamble technique. They 
found a net loss in utility of 0.027, but did not report any difference by 
drug [23]. The present findings are consistent with the WHO CHOICE 
by Murray, et al. [6]: the absolute risk approach also had lower cost-
effectiveness ratios than the target-level approach. The present study 
extends their findings in distinct ways. First, we looked at a specific 
country with more detailed epidemiological and cost data. This allows 
an individual country like Italy to shift resources based on its specific 
health needs and budgetary limitations. It allows a direct comparison 
of the two possible approaches under consideration and evaluation of 
what a change from its current approach to a new one might entail. 
Second, our model included inpatient costs of cardiovascular events. 
Given that these events are responsible for a significant proportion of 
costs related to a blood pressure and cardiovascular disease prevention 
program, our costs more likely reflect actual costs associated with the 
intervention. Additionally, a recent study in a busy primary care setting 
in the United Kingdom found that use of a chart based on absolute 
risk calculations was well-liked, easy to use, and resulted in a clinically 
significant reduction in blood pressure compared with usual care [24]. 
One limitation is that the absolute risk approach uses the Framingham 
function, which is based on a predominantly US white population. 
However, it has been shown to be equally predictive among white and 
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black men and women in the United States [25]. Furthermore, the 
case-control INTERHEART study confirmed that similar risk factors 
accounted for the majority of myocardial infarction regardless of 
region [26]. Further generalization of our results to other developing 
countries should take into account the fact that the risk score may 
overestimate or underestimate disease, which would increase or 
decrease the incremental cost-effectiveness ratios, respectively.
Conclusions
We stated that our results were comparable with the findings 
published in a study from the WHO CHOICE program. In terms 
of the issue of the generalizability of the study results to other 
developing countries, we noted that risk scores might overestimate 
or underestimate disease, thus caution is required when extrapolating 
the results of the study to other settings. Several sensitivity analyses 
might be performed, which further enhance the external validity of the 
study. A potential limitation of the analysis was that the estimation of 
risk factors was based on a predominantly Italian white population. 
Hypertension guidelines based on an absolute risk for cardiovascular 
disease could be both more effectiveness and less expensive than 
guidelines based mainly on blood pressure level. Reductions in the 
cost of antihypertensive drugs could even make this guideline cost-
saving in comparison with no intervention. The study results support 
the use of hypertension guidelines based on the assessment of absolute 
cardiovascular risk among healthy individuals.
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